Archive: Company News
Curexsys Appoints Christian Eckert as Chief Operating Officer
– Strengthened management team headed by Jörg Neermann as CEO
Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Eckert, PhD, as Chief Operating Officer. He joins Curexsys´ recently expanded management board which consists of Jörg Neermann, PhD, Chief Executive Officer, and the Company´s co-founder Jens Gruber, PhD, Chief Scientific Officer.
ImmunOs Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)
– Preclinical data highlighting mode-of-action of lead program iosH2
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that the Company will present a scientific poster at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting (SITC) which will be held November 10-14, 2021, in Washington, DC, USA.
Launch of Capitainer® B Vanadate, a blood sampling card that eliminates the risk of inaccurate test results when analyzing PEth
Swedish medtech scaleup Capitainer today announced the launch of its proprietary patent pending blood sampling card, Capitainer B Vanadate for accurate analysis of PEth, a key marker for long term alcohol use/abuse.
Dried Blood Spot (DBS) sampling has been proposed as a method to solve the problem of post sampling formation of PEth occurring in traditional venous blood samples. However, the hematocrit effect gives negative impact on the accuracy due to uncertainty of the blood volume in DBS. Capitainer B Vanadate solves both problems in the same device and creates a new better standard.
T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
— Presentations to cover preclinical data for lead TCR-T candidate, TK-8001, and the protocol design for a Phase 1/2 trial of TK-8001 to treat MAGE-A1 positive solid tumors
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that three abstracts highlighting its lead product candidate TK-8001, a T cell receptor (TCR) engineered T cell therapy (TCR-T) being developed to treat MAGE-A1 positive solid tumors, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting taking place November 10-14, 2021.